Second half of Zealand Pharma's congenital hyperinsulinism study data revealed at conference

The biotech company has now presented all top-line data from a two-part phase III study, demonstrating that dasiglucagon can reduce the duration of low blood sugar episodes.

Photo: Zealand Pharma / PR

Zealand Pharma’s dasiglucagon, a glucagon analog designed treat congenital hyperinsulinism, CHI, has demonstrated a statistical significant reduction in the duration of low blood sugar episodes known as hypoglycemia that characterize the disease, the company reveals in an announcement.

These top-line results come from the second part of a phase III study of dasiglucagon, where Zealand Pharma tested the drug over 21 days in infants with CHI, and were presented at the annual European Society for Pediatric Endocrinology (ESPE) meeting, held in Rome in mid-September.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs